Computational Investigation of Pkcβ Inhibitors for the Treatment of Diabetic Retinopathy

Susmitha Valli Gogula1*, Ch Divakar2, Ch Satyanarayana3, Yedla Phani Kumar3, Vadapalli Santhosi Lavanaya3

1Department of IT, GITAM University, Patancheru Mandal, Medak Dist-502329; 2Pydah College of Engineering and Technology, Gambheeram, Anandapuram (M); Visakhapatnam-531163; 3Jawaharlal Nehru Technological University Kakinada, Kakinada, Andhra Pradesh-533003; Susmitha Valli Gogula – Email: susmitagv@gmail.com; *Corresponding author

Received December 05, 2013; Accepted December 19, 2013; Published December 27, 2013

Abstract:
Diabetic Retinopathy (DR) is one of the attenuating complications of diabetes mellitus. The key gene responsible for causing diabetic retinopathy is protein kinase C beta (PKCβ). Protein kinase C is a family of protein kinase enzymes which are involved in controlling the function of other proteins through phosphorylation mechanism and plays a crucial role in signal transduction mechanisms. Among all the PKC isoenzymes, PKCβ could be a significant isoenzyme involved in vascular dysfunction during hyperglycemia. Studies show that oral administration of PKCβ inhibitor Ruboxistaurin (LY333531), decreases vessel permeability and improves retinal condition. Thus compounds that decrease the PKCβ activation would be helpful in the treatment of diabetic retinopathy.

The compounds similar to Ruboxistaurin are taken from Super Target database and docking analysis was performed. Maleimide derivative 3 showed highest binding affinities compared to Ruboxistaurin and so we advise that compound may be utilized in the treatment of diabetic retinopathy.

Keywords: PKCβ, Ruboxistaurin, Diacylglycerol (DAG), Diabetic retinopathy (DR)

Background:
Diabetes mellitus is a metabolic disorder in which blood glucose levels are increased due to insulin deficiency or insulin resistance. Type 1 diabetes results from body’s failure to produce insulin which leads to insulin deficiency. In type 2 diabetes, cells in the body do not react to insulin (insulin resistance). One of the complications of diabetes is diabetic retinopathy which causes injury to tissue layer and eventually leads to vision loss. DR is clinically characterized by micro vascular dysfunction, with retinal vessels basement membrane thickening, loss of pericytes and endothelial cells, blood retinal barrier breakdown, capillary non perfusion, cotton wool spots formation and neo vascularisation [1]. Based on the methods like clustalw and phylogenetic tree construction several proteins involved in the pathogenesis of diabetic retinopathy are identified [2, 3, 4] and shows that BDNF [5], aldose reductase, nitric oxide synthase have role in diabetes and its complications [3]. On scrutinizing we tend to take PKCβ and its role in diabetic retinopathy. In hypoglycemic conditions, DAG-PKC pathway plays a major role by which increase within the levels of DAG leads to PKC activation. DAG is derived from the hydrolysis of phosphatidylinositol 4-5 bisphosphate, by a membrane bound enzyme phospholipase C - (PLC) [6]. DAG-PKC pathway can also be activated by hyperglycemia induced oxidants such as H2O2 which are known to activate PKC either directly or by increasing DAG production [7, 8]. In early stages increase in DAG may activate PKC and in advanced stages, when VEGF levels are elevated PKC plays an important role in modulation of VEGF action and as a stimulator of VEGF expression. PKC activation induced by hyperglycemia could alter the expression of various growth factors like VEGF that induces retinal vessel permeability. PKCβ activation affects VEGF expression through the mRNA-stabilizing human embryonic lethal abnormal vision (ELAV) protein, HuR, in the retina [9]. Previous work additionally explains that in order to test the linearity of the multiple sequences at a time for a
number of proteins general regression model technique algorithm (GRMT1) can be used and high accuracy sequence clustering can also be done by using a clustering algorithm [10]. Inhibition of PKC\(\beta\) leads to prevention of glucose induced increase in VEGF expression [11, 12] (Figure 1). Hence oral administration of PKC\(\beta\) inhibitor LY333531 will forestall or reverse blood retinal barrier breakdown by inhibiting VEGF expression. Ruboxistaurin or LY333531 could be a competitive inhibitor that acts by interacting with the ATP binding site [13, 14] which shows selectivity towards PKC and hence found to be an important therapeutic agent for diabetic retinopathy.

Inhibition of PKC\(\beta\) leads to prevention of glucose induced increase in VEGF expression [11, 12] (Figure 1). Hence oral administration of PKC\(\beta\) inhibitor LY333531 will forestall or reverse blood retinal barrier breakdown by inhibiting VEGF expression. Ruboxistaurin or LY333531 could be a competitive inhibitor that acts by interacting with the ATP binding site [13, 14] which shows selectivity towards PKC and hence found to be an important therapeutic agent for diabetic retinopathy.

Methodology:

Preparation of proteins and ligands

The three dimensional structure of Protein kinase C beta receptor of homosapiens was retrieved from the Protein Databank (PDB: Id 1A25). The list of compounds similar to potent PKC\(\beta\) inhibitor Ruboxistaurin were obtained from Super Target Database. The 3D SDF format of ligand molecules were obtained from NCBI Pubchem.

### Ligand molecules

Based on the Lipinski five rules, the ligand molecules which are similar to Ruboxistaurin were taken from Super Target Database. The ligand molecule which obeys Lipinski rule were taken and used for docking studies is 20.

### Energy minimization

Energy minimization studies were carried for both protein and ligand molecules by using SYBYL software by applying tripos force field, gasteiger- huckel charges were calculated.

### Protein networking prediction

The protein interaction network for PKC\(\beta\) and VEGF was obtained from String 9.05 database [15] (Figure 2).

Methodology:

#### Preparation of proteins and ligands

The three dimensional structure of Protein kinase C beta receptor of homosapiens was retrieved from the Protein Databank (PDB: Id 1A25). The list of compounds similar to potent PKC\(\beta\) inhibitor Ruboxistaurin were obtained from Super Target Database. The 3D SDF format of ligand molecules were obtained from NCBI Pubchem.

#### Ligand molecules

Based on the Lipinski five rules, the ligand molecules which are similar to Ruboxistaurin were taken from Super Target Database. The ligand molecule which obeys Lipinski rule were taken and used for docking studies is 20.

#### Energy minimization

Energy minimization studies were carried for both protein and ligand molecules by using SYBYL software by applying tripos force field, gasteiger- huckel charges were calculated.

#### Protein networking prediction

The protein interaction network for PKC\(\beta\) and VEGF was obtained from String 9.05 database [15] (Figure 2).

**Figure 1:** Role of PKC\(\beta\) in Diabetic Retinopathy.

![PKC\(\beta\) in Diabetic Retinopathy](image1)

**Figure 2:** Protein interaction network obtained from string database

![Protein interaction network](image2)

**Figure 3:** Docking conformations showing the interaction of Ruboxistaurin to PKC\(\beta\). Aminoacid residues showing bonded and non bonded interactions are represented in Black. Ligand molecules are shown in ball and stick representation.

![Docking conformations](image3)

**Figure 4:** Docking conformations showing the interaction of Maleimide derivative 3 to PKC\(\beta\). Aminoacid residues showing bonded and non bonded interactions are represented in Black. Ligand molecules are shown in ball and stick representation.

![Docking conformations](image4)
initial population of 150 individuals, Lamarckian genetic algorithm (LGA) was implemented with a maximum of 2500000 energy evaluations and maximum number of generations was 27000. This gives the best ten binding orientations of ligand molecules to its receptor.

**Screening of lead molecule for its activity and drug likeliness properties**

The molecular properties of ligands like log P, number of hydrogen bonds, number of atoms, molecular weight were obtained using molinspiration program **Table 1 (see supplementary material)**. This tool also provides number of violations which mean that there is a deviation from Lipinski 5 rule. Those compounds having more than one violation were eliminated and remaining compounds were used for docking studies i.e., CHEMBL315357, CHEMBL91959, CHEMBL328229, CHEMBL321529, CHEMBL103055, CHEMBL421217, CHEMBL130774, CHEMBL336179, CHEMBL321315, CHEMBL105477.

**Results & Discussions:**

**Interaction of ligands**

Docking results between PKCβ and maleimide derivative 3 found to be good as it was giving lowest docking energy (-9.36 kcal/mol) than ruboxistaurin (-8.61 kcal/mol) **Table 2 (see supplementary material)** (Figure 3 & Figure 4). By analyzing the docked conformations, interaction of PKCβ—ruboxistaurin (reference ligand) showed formation of hydrogen bond between oxygen atom at Met256 of PKCβ and hydrogen at 51st position of ligand molecule **Table 3 (see supplementary material)**. The non hydrogen bonds include interaction between Nitrogen at Met256—with oxygen at 2nd position and additionally with oxygen at 1st position; Nitrogen at Gly257—oxygen at 2nd position; Nitrogen at Phe255—nitrogen at 6th position. Interaction between PKCβ—maleimide derivative 3, showed non hydrogen bond interactions between Nitrogen at Met256 of PKCβ—nitrogen at 4th position and also with oxygen at 1st and 2nd position of maleimide derivative 3; Nitrogen at Gly257—nitrogen at 4th. Binding energy value of Bisindolylmaleimide I from Autodock was found to be (-9.14 kcal/mol). Interaction between PKCβ—Bisindolylmaleimide I, showed hydrogen bond between oxygen at Phe255 of PKC β and hydrogen at 45th position of ligand molecule. The non bound interactions are between nitrogen at Gly257—oxygen at 2nd position; amine at Arg159—oxygen at 1st position. The binding energy of CHEMBL316239 from Autodock was (-9.12 kcal/mol).

**Conclusion:**

Of all the molecules obtained from the database, maleimide derivative 3, showed highest binding affinity than Ruboxistaurin by forming bonded and non bonded interactions towards PKCβ. We therefore suggest that maleimide derivative 3 is a potent inhibitor of PKCβ and may be useful in treatment of diabetic retinopathy. The potent inhibition can be discovered through in vivo and in vitro studies.

**References:**

[1] Aiello, & Lloyd Paul, *Survey of ophthalmology*. 2002 47: 5263
[2] Sridhar GR et al. *Int J Diabetes Dev Ctries*. 2006 26: 149
[3] Rao AA et al. *Med Hypotheses*. 2008 70: 148
[4] Leal EC et al. *Current Drug Targets-CNS & Neurological Disorders*. 2005 4: 421 [PMID: 16101558]
[5] Rao, AA et al. *Medical hypotheses*, 2008 70: 424 [PMID: 17553627]
[6] Nishizuka Y et al. *Science*. 1992 258: 607
[7] Konishi H et al. *Proc Natl Acad Sci USA*. 1997 94: 11233 [PMID: 9326592]
[8] Nishikawa T et al. *Nature* 2000 404: 787 [PMID: 10783895]
[9] Amadio M et al. *Biochem Pharmacol*. 2010 80: 1230 [PMID: 20599775]
[10] Devi GL et al. *IJCNS*. 2008 8: 225
[11] Williams B et al. *Diabetes*. 1997 46: 1497
[12] Poulaki V et al. *J Clin Invest*. 2002 109: 805
[13] Jirousek MR et al. *J Med Chem* 1996 39: 2664 [PMID: 8709095]
[14] Strom Charlotte et al. *Investigative ophthalmology & visual science*. 2006 46: 3855 [PMID: 16186374]
[15] Franceschini Andrea et al. *Nucleic acids research*. 2013 41: D808 [PMID: 23203871]
[16] Morris GM et al. *J Comput Chem*. 2009 30: 2785 [PMID: 19399780]

**License statement:** This is an open-access article, which permits unrestricted use, distribution, and reproduction in any medium, for non-commercial purposes, provided the original author and source are credited

**Edited by P Kangueane**
Supplementary material:

Table 1: Molinspiration analysis of ligand molecules.

| NCompound   | Molopoly | molecular polar surface area | Num of atoms | molecular weight | number of H-bond acceptors | Number of H-bond donors | Num of violations | Number of rotatable bonds | Volume |
|-------------|----------|-------------------------------|--------------|-----------------|---------------------------|------------------------|-------------------|--------------------------|--------|
| 1 CHEMBL311543 | 3.49     | 81.062                        | 34.0         | 454.53          | 7                         | 2                      | 0                 | 2                        | 409.057 |
| 2 CHEMBL419866 | 4.13     | 72.273                        | 37.0         | 494.595         | 7                         | 1                      | 0                 | 2                        | 449.243 |
| 3 CHEMBL316239 | 2.51     | 95.058                        | 33.0         | 440.503         | 7                         | 3                      | 0                 | 1                        | 391.383 |
| 4 ZINC03825435 | 3.07     | 89.263                        | 33.0         | 441.487         | 7                         | 2                      | 0                 | 1                        | 388.112 |
| 5 CHEMBL432130 | 3.73     | 72.273                        | 35.0         | 468.557         | 7                         | 1                      | 0                 | 2                        | 426.000 |
| 6 CHEMBL31035  | 3.24     | 78.269                        | 33.0         | 441.487         | 7                         | 1                      | 0                 | 0                        | 389.053 |
| 7 CHEMBL294120 | 3.34     | 89.263                        | 34.0         | 455.514         | 7                         | 2                      | 0                 | 1                        | 404.913 |
| 8 Bisindolylmaleimide I | 3.83     | 73.896                        | 31.0         | 412.493         | 6                         | 2                      | 0                 | 6                        | 377.044 |
| 9 maleimide derivative, 3 | 4.84     | 58.105                        | 32.0         | 423.516         | 5                         | 1                      | 0                 | 6                        | 392.059 |

Table 2: Docking energies of different ligand molecules.

| No  | Name of the ligands               | Docking energies | Bonded interactions             |
|-----|-----------------------------------|------------------|---------------------------------|
| 1   | Ruboxistaurin (Reference)         | -8.61            | Met256,Gly257                   |
| 2   | maleimide derivative, 3           | -9.36            | Met256,Gly257                   |
| 3   | Bisindolylmaleimide I             | -9.14            | Arg159,Gly257, Phe255           |
| 4   | CHEMBL316239                      | -9.12            | Phe255, Met256, Gly257          |
| 5   | CHEMBL311543                      | -8.88            | Arg159                         |

Table 3: bonded and non bonded interactions between receptor and ligand molecules.

| PKCβ maleimide derivative 3 | PKCβ Bisindolylmaleimide I | PKCβ CHEMBL316239 | PKCβ CHEMBL311543 |
|-----------------------------|---------------------------|-------------------|-------------------|
| Met256:N→O2                 | Met256:N→N4               | Arg159:N→O1       | Phe255:N→O3       | Arg159:NH1→N7         |
| Met256:N→O1                 | Met256:N→O2               | Arg159:NH1→O1     | Met256:N→O3       | Arg159:NH2→N7         |
| Gly257:N→O2                 | Gly257:N→N4               | Arg159:NH2→O1     | Met256:N→O1       |                    |
| Phe255:N→N6                 | Met256:N→O1               | Gly257:N→O2       |                   |                    |
| Met256:O→H51                |                           |                   |                   |                    |